← Eichor
Condition: Mds Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mds

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Activity Levels in Bone Marrow Transplant Patients
Phase N/A · 1 location(s) · Michael Tomasson · NCT04115241A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Ce
Phase 1 · 21 location(s) · TScan Therapeutics, Inc. · NCT05473910Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod
Phase 3 · 62 location(s) · Institut de Recherches Internationales Servier · NCT06465953MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 2 · 1 location(s) · University of Manitoba · NCT06599762Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT06484062Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
NA · 3 location(s) · University Hospital, Bordeaux · NCT05924074Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Im
Phase 1 · 22 location(s) · Taiho Oncology, Inc. · NCT04953910MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
NA · 3 location(s) · University of Miami · NCT05745285Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administer
Phase 1/Phase 2 · 11 location(s) · Ionis Pharmaceuticals, Inc. · NCT06430385A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT07019155CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1 · 11 location(s) · Cullinan Therapeutics Inc. · NCT05143996A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06566742Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Do
Phase 1 · 5 location(s) · Celyad Oncology SA · NCT04167696A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
Phase 1 · 10 location(s) · Taiho Pharmaceutical Co., Ltd. · NCT04608110A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1 · 14 location(s) · Ascentage Pharma Group Inc. · NCT04275518Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NA · 7 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04587856Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syn
Phase 3 · 2 location(s) · Ascentage Pharma Group Inc. · NCT06641414Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.